Kilburn, L., Landi, D., Leary, S., Ziegler, D., Baxter, P., Franson, A., … Hansford, J. (2022). CTNI-68. FIREFLY-1 (PNOC026): Phase 2 study of pan-RAF inhibitor tovorafenib in pediatric and young adult patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors. In Neuro-Oncology (Vol. 24, pp. vii89–vii89). Tampa Convention Center, Tampa Bay, FL: Oxford University Press. https://doi.org/10.1093/neuonc/noac209.333

Kilburn, Lindsay, Daniel Landi, Sarah Leary, David Ziegler, Patricia Baxter, Andrea Franson, Geoffrey McCowage, et al. “CTNI-68. FIREFLY-1 (PNOC026): Phase 2 study of pan-RAF inhibitor tovorafenib in pediatric and young adult patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors.” In Neuro-Oncology, 24:vii89–vii89. Oxford University Press, 2022. https://doi.org/10.1093/neuonc/noac209.333.

Kilburn L, Landi D, Leary S, Ziegler D, Baxter P, Franson A, et al. CTNI-68. FIREFLY-1 (PNOC026): Phase 2 study of pan-RAF inhibitor tovorafenib in pediatric and young adult patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors. In: Neuro-Oncology. Oxford University Press; 2022. p. vii89–vii89.

Kilburn, Lindsay, et al. “CTNI-68. FIREFLY-1 (PNOC026): Phase 2 study of pan-RAF inhibitor tovorafenib in pediatric and young adult patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors.” Neuro-Oncology, vol. 24, no. 7, Oxford University Press, 2022, pp. vii89–vii89. Manual, doi:10.1093/neuonc/noac209.333.

Kilburn L, Landi D, Leary S, Ziegler D, Baxter P, Franson A, McCowage G, Waanders A, Van Der Lugt J, Oren M, Gerber N, Gottardo N, Khuong-Quang D-A, Nysom K, Bailey S, Driever P, Perreault S, Witt O, Hahn S, Hargrave D, Hassall T, Nada J, Jin Kang H, Larouche V, Toledano H, Cassie K, Abdelbaki M, Chi S, Gardner S, Whipple N, Mueller S, Blackman S, Zhao X, Da Costa D, Cox M, Packer R, Hansford J. CTNI-68. FIREFLY-1 (PNOC026): Phase 2 study of pan-RAF inhibitor tovorafenib in pediatric and young adult patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors. Neuro-Oncology. Oxford University Press; 2022. p. vii89–vii89.